Member Info for researcher1

hi phant - odd you say that, but the LSE platform seems to have changed about 3 times in the last 2 months in terms of the 'thread' protocols - wonder if it is a Chrome/Safari thing?

if it eventually transfers fully, that is....

I like the thinking ahead - any idea how Nasdaq would impact that?

good advice Phantom - but don't take too long to decide Crisp! - also do read some of the research paper RNSs to get an idea of the significance of Parsortix....

maybe it was all the capital letters....

I agree this is a strong buy, but to appear suddenly with such an obvious rampy post suggests you are being paid iceman, so please go away.

if you check back through this BB you will see various arguments over future value, and I can assure you I am at the low end of the scale - and all the predictions (up to £15 - £20 per share) are based on what Andrew Newland has himself said over the past three years - since which time there have been several more world-class trials and academic papers. It will take a timely FDA approval and around three more contracts to take it to £3+ and then we'll have to see which big players are interested....

I think with a share like AGL, with so much revenue in front of it, RSI is only likely to work short term (weeks, not months), and then it will start showing 'overbought' consistently - as do all my best shares. I'm with Jelenko - identify your companies and just keep buying up to your target (mine is £4 to take original stake out - £50K - and stop buying, £6 to top slice 20%, then the rest stays in until 2025, when I'll need to buy Tobago). AN can have Trinidad.

I am today in 100% profit here!!! celebration time (and top slice time - I'm putting £20K of that profit into Angle). Well done everyone - more to come I'm sure, it's just that Angle is set for lift-off...

RSI systems are notoriously fallible when movement is news-driven however.....

you need to control that twitch Phantom, we don't know how long the FDA will need, so you may be jumpity for months.
Relax instead in the knowledge that half a dozen (and more) institutions with world-class reputations have verified Parsortix's credentials...

agreed, we need FDA first in order to leap forward - the clinics are slow building blocks....
AN has certainly mentioned £4-5B MCAP as targets, which is obviously a lot more than £4 (5 x more in fact) so in due course we can consider where is realistic, at what point, in relation to market penetration and so on....

I'll see if I can find the exact wording - I understood it meant £6 per share

it was in response to an online question I posed, asking if US investors were concerned that the price had gone down since their investment - so about this time last year? I assume he was speaking approximately, but replied to the effect that the US investors were not concerned about small movements in the SP as they were in for tenfold gains.

Phantom, ok, we'll agree to disagree on the £4, but I think you've misconstrued me, so to speak, in that it was a minimum I was seeking to establish, not a likely or realistic figure. Personally I am using AN's comment that US investors were anticipating a tenfold return (on their 60p investment) as my touchstone. So when we get close to £6 I'll start to top slice.

well you didn't factor in the bonus shares to AN's remuneration, or his salary for 15 years, which would take it over your £50M, but anyway let's agree that £4 a share would be an absolute minimum for his company AS IS.

no probs ted - most of my Angle shares were bought at 40p, so fairly happy at the moment, especially as the big news is still a few weeks away, as with SBTX. Both could easily double...

only 30p to go to hit the current broker target - £1.50 (or £1.40 if you follow Zak Mir) would be a fantastic launch pad for FDA approval - £3 on the day, £4 a week later. THEN I will accept that AN would not be tempted by £4!

that was me Ted :-)

I would totally agree with them tom - I'm just running scenarios....